At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
JZP-110 +1 moredrug
Likely dose
JZP-110 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
In Brief
A Phase 2 clinical trial evaluating JZP-110 and Placebo for Excessive Sleepiness and Parkinson Disease. Completed, enrolled 66 participants across 25 sites.
Detailed Summary
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExcessive Sleepiness, Parkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedJan 31, 2017
Enrollment StartJan 1, 2017
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.4 years ago
Interventions
JZP-110drug
75 mg, 150 mg, 300 mg
Placeboother